1月 7, 2021 | 未分类
SAN DIEGO, Jan. 7, 2021 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Gary Yeung, CFA, MBA, as Chief Financial Officer and Chief Operating Officer. Mr. Yeung brings extensive...
1月 4, 2021 | 未分类
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- Ambrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or...
12月 10, 2020 | 未分类
• 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU
• Multiple Global Phase...
11月 9, 2020 | 未分类
SAN DIEGO, November 9, 2020 – Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code announced today the successful closing of an oversubscribed...
1月 13, 2020 | 未分类
Sino Biopharma receives exclusive rights to develop and commercialize two Ambrx enabled drug products in China Ambrx receives upfront payment plus undisclosed milestone payments and royalties.
SAN DIEGO, USA and BEIJING,...
